Cell-Compatible Tissue Clearing Composition
By applying nucleotides or their derivatives to biological tissues, the method achieves transparency while preserving cell viability, enabling deep tissue observation and evaluation.
Patent Information
- Application Number
- JP2021548987
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-24
- Filing Date
- 2020-09-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-09-24
AI Technical Summary
Existing methods for making biological tissues transparent often require fixing the tissue with formaldehyde, leading to cell death and collapse of the cell structure, preventing observation of minute molecules like membrane proteins, and do not allow for deep three-dimensional observation of living tissues.
Applying a solution containing nucleotides, nucleotide derivatives, or polymers of nucleotides to biological tissues to make them transparent while maintaining living cells, using compounds such as AMP, ADP, and polyA to achieve refractive index matching and transparency.
Enables deep three-dimensional observation of living tissues, allowing visualization of blood vessels and gene expression without cell death, facilitating accurate evaluation of grafts and contributing to pharmaceutical and medical research.
Smart Images

Figure 0007579578000002 
Figure 0007579578000003 
Figure 0007579578000004
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for making biological tissue transparent, and a composition and a kit therefor. In particular, the present invention relates to a method for making biological tissue transparent in a living state, and a composition and a kit therefor. [Background technology]
[0002] In medical treatment and drug discovery research, it is important to accurately observe the three-dimensional structure of biological tissues, organs, or three-dimensional tissue models using a confocal laser microscope or the like. However, biological tissues are usually opaque and do not transmit light well, so the observation depth is limited to 100 to 200 μm. In recent years, various methods for making tissue transparent have been reported. Most of these methods increase the light transmittance by replacing water with organic molecules with a high refractive index to match the refractive index of biomolecules (see Patent Document 1, etc.). In addition, a method for lowering the refractive index of tissues by removing lipids with a high refractive index has also been reported (see Patent Document 2, etc.).
[0003] However, because the cells die after these treatments, it is necessary to fix the tissue with formaldehyde, etc., and no method has been reported to achieve transparency while the cells are still alive. In addition, after removing the lipids (cell membrane), the cell structure collapses, making it impossible to observe minute molecules such as membrane proteins. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Patent Application No. WO2015 / 022883 [Patent Document 2] International Patent Application No. WO2017 / 188264 Summary of the Invention [Problem to be solved by the invention]
[0005] It was necessary to make tissues and organs transparent while keeping cells alive, and to enable deep three-dimensional observation. [Means for solving the problem]
[0006] The inventors have conducted extensive research to solve the above problems and have discovered that biological tissue can be made transparent in a living state by applying to the biological tissue a solution containing one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers, thereby completing the present invention.
[0007] That is, the present invention provides the following. (1) A method for making biological tissue transparent in a living state, comprising applying to the biological tissue a solution containing one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and polymers of nucleotides. (2) The method according to (1), wherein the compound is one or more compounds selected from the group consisting of AMP, CMP, TMP, ADP and polyA. (3) The method according to (2), wherein the compound is one or more compounds selected from the group consisting of AMP, ADP and polyA. (4) A composition for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers. (5) The composition according to (4), wherein the compound is one or more compounds selected from the group consisting of AMP, CMP, TMP, ADP and polyA. (6) The composition according to (5), wherein the compound is one or more compounds selected from the group consisting of AMP, ADP and polyA. (7) A kit for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers. (8) The kit according to (7), wherein the compound is one or more compounds selected from the group consisting of AMP, CMP, TMP, ADP and polyA. (9) The kit according to (8), wherein the compound is one or more compounds selected from the group consisting of AMP, ADP and polyA. (10) A method for observing biological tissue, comprising making the biological tissue live and transparent by using the method according to any one of (1) to (3), the composition according to any one of (4) to (6), or the kit according to any one of (7) to (9), and observing the inside of the biological tissue. (11) A method for producing a biological tissue that has been made transparent in a living state, comprising using the method according to any one of (1) to (3), the composition according to any one of (4) to (6), or the kit according to any one of (7) to (9). Effect of the Invention
[0008] According to the present invention, since the living tissue can be made transparent in a living state, the state of the deep part of the living tissue can be observed as it is. It is possible to observe the state of blood vessels and lymphatic vessels in the deep part of the living tissue, gene expression, localization of substances, etc. over time. In addition, since not only the surface but also the deep part of the graft can be observed, the graft can be accurately evaluated. Therefore, it can be said that the significance of being able to make the living tissue transparent in a living state is extremely great in the development of pharmaceuticals, medical and pharmaceutical research, etc. Furthermore, the compound used in the present invention can be a commercially available one, and is inexpensive. [Brief description of the drawings]
[0009] [Figure 1] The upper panel of Fig. 1 is a photograph showing the collagen solution clarifying effect of AMP, ADP, ATP, CMP, TMP and poly A. The lower panel of Fig. 1 is a graph showing the light transmittance of collagen solutions treated with AMP, ADP, ATP, CMP, TMP and poly A. * indicates 100% by weight, ** indicates 25% by weight. [Diagram 2] FIG. 2 is a set of photographs and a graph showing the results of investigating the effects of AMP concentration and collagen concentration on clearing. [Diagram 3] Figure 3 shows photographs of the appearance of the artificial 3D tissue model before and after AMP treatment (upper left panel: before treatment, upper right panel: after treatment), and confocal laser microscope photographs of blood vessels inside the tissue stained with CD31 antibody (lower left panel: before treatment, lower right panel: after treatment). All photographs in Figure 3 were taken from a perpendicular angle to the dish. [Figure 4] Figure 4 shows confocal laser microscope images of blood vessels inside the tissue of an artificial 3D tissue model before and after AMP treatment (upper left panel: before treatment, upper right panel: after treatment). Blood vessels were stained with CD31 antibody. These images were taken from a horizontal angle relative to the dish. The lower right panel of Figure 4 is a confocal laser microscope image of the entire vascular network after clearing treatment. [Diagram 5] The top of Fig. 5 shows images immediately before treatment (0 min), the left panel shows images observed vertically to the dish, and the right panel shows images observed horizontally to the dish. The bottom of Fig. 5 shows images immediately after treatment (30 min), the left panel shows images observed vertically to the dish, and the right panel shows images observed horizontally to the dish. [Figure 6] The left panel of Figure 6 shows cell viability after 30 minutes of clearing with AMP, RapiClear 1.52, and fructose. The right panel of Figure 6 shows the relationship between the time of clearing with AMP and cell viability. In the figure, Rap stands for RapiClear 1.52, and Fru stands for fructose. ** indicates p<0.01, and NS indicates no significance. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] In one aspect, the present invention provides a method for making biological tissue transparent in a living state, which comprises applying to the biological tissue a solution containing one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and polymers of nucleotides.
[0011] The nucleotide, nucleotide derivative, polymer having a nucleotide or nucleotide derivative, and nucleotide polymer used in the present invention may be any one having a transparentizing ability. A nucleotide is a compound in which a phosphate group is bound to a nucleoside. A nucleoside is a compound in which a base is bound to the like. Typical bases include, but are not limited to, purine bases such as adenine and guanine, and pyrimidine bases such as thymine, cytosine, and uracil. Nicotinamide and dimethylisoalloxazine are also examples of bases. Typical sugars include, but are not limited to, ribose and deoxyribose. A nucleotide containing ribose as a sugar is called a ribonucleoside, and a nucleotide with a phosphate group bound thereto is called a ribonucleotide. A nucleoside containing deoxyribose as a sugar is called a deoxyribonucleoside, and a nucleotide with a phosphate group bound thereto is called a deoxyribonucleotide.
[0012] A nucleotide polymer refers to a compound in which two or more nucleotides are linked by a phosphodiester bond between the phosphate group of one nucleotide and the sugar of another nucleotide. Typical nucleotide polymers include ribonucleotide polymers and deoxyribonucleotide polymers. In the present invention, a nucleotide polymer may be a ribonucleotide polymer, a deoxyribonucleotide polymer, or a ribonucleotide and deoxyribonucleotide polymer.
[0013] Typical nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers that can be used in the present invention are described below.
[0014] Examples of ribonucleotides include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), 5-methyluridine monophosphate (TMP), 5-methyluridine diphosphate (TDP), 5-methyluridine triphosphate (TTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), inosine monophosphate (IMP), inosine diphosphate (IDP) and inosine triphosphate (ITP).Preferred ribonucleotides include AMP, ADP, ATP, CMP, GMP, IMP, TMP and UMP, and more preferred ribonucleotides include AMP, ADP, CMP and TMP. More preferred ribonucleotides include AMP and ADP.
[0015] Examples of deoxyribonucleotides include, but are not limited to, deoxyadenosine monophosphate (dAMP), deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), thymidine monophosphate (dTMP), thymidine diphosphate (dTDP), thymidine triphosphate (dTTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP), deoxyuridine triphosphate (dUTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP) and deoxycytidine triphosphate (dCTP).Preferred deoxyribonucleotides include dAMP, dGMP, dTMP, dUMP and dCMP.More preferred deoxyribonucleotides include dTMP.
[0016] Various nucleotide derivatives are known. Derivatization includes, but is not limited to, alkylation, esterification, halogenation, addition of phosphate, addition of amino acid or peptide, addition of heterocycle, and the like. Nucleotides may also be cyclized within a molecule. A typical example of a cyclized nucleotide is cyclic AMP (cAMP), but is not limited to this. The nucleotide from which the nucleotide derivative is derived may be a ribonucleotide or a deoxyribonucleotide.
[0017] A polymer having a nucleotide or a nucleotide derivative refers to a polymer having a backbone to which a nucleotide or a nucleotide derivative is bound. For example, an appropriate number of nucleotides or nucleotide derivatives may be bound via functional groups of a polysaccharide or a polypeptide. For example, a portion of the sugar residues of a polysaccharide or the amino acid residues of a polypeptide may be replaced with a nucleotide or a nucleotide derivative. The nucleotides in such a polymer may be ribonucleotides, deoxyribonucleotides, ribonucleotides and deoxyribonucleotides, or derivatives thereof.
[0018] The nucleotides constituting the nucleotide polymer may be ribonucleotides, deoxyribonucleotides, or ribonucleotides and deoxyribonucleotides. The ribonucleotide polymer may be composed of one type of ribonucleotide, or may be composed of two or more types of ribonucleotides. A preferred example of the ribonucleotide polymer is polyA polymerized with AMP, but is not limited thereto. The molecular weight of the ribonucleotide polymer is not particularly limited, but may be, for example, about 100 to several hundred kDa. The deoxyribonucleotide polymer may be composed of one type of deoxyribonucleotide, or may be composed of two or more types of deoxyribonucleotides. The molecular weight of the deoxyribonucleotide polymer is not particularly limited, but may be, for example, about 100 to several hundred kDa.
[0019] A part or all of the nucleotides constituting the polymer may be nucleotide derivatives.
[0020] Various nucleotides are commercially available and can be used in the present invention. In addition, chemical and enzymatic synthesis methods of nucleotides are also known. Various nucleotide polymers are commercially available and can be used. In addition, methods for synthesizing nucleotide polymers are also known, including solid-phase synthesis and liquid-phase synthesis. A typical solid-phase synthesis method is the phosphoramidite method. Methods for synthesizing nucleotide derivatives are also known. Methods for synthesizing polymers having nucleotides or nucleotide derivatives are also known. Those skilled in the art can obtain desired nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers using known synthesis methods.
[0021] The nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers used in the present invention preferably have low or no toxicity to cells.
[0022] In the present invention, one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and nucleotide polymers may be used. For example, AMP and polyA may be used in combination.
[0023] In the method of the present invention, a solution containing the above-mentioned compound is applied to a biological tissue. The solution can be prepared by dissolving the above-mentioned compound in water or a buffer solution. The buffer solution is known and can be appropriately selected. Examples of the buffer solution include, but are not limited to, Tris-HCl buffer solution, phosphate buffer solution, phosphate buffered saline, etc.
[0024] The concentration of the compound in the solution is preferably such that the refractive index of the solution is about 1.35 or more, preferably about 1.4 or more. Since the refractive index varies depending on the compound, the concentration to obtain the desired refractive index also varies depending on the compound. The selection of the compound and the adjustment of its concentration are within the skill of a person skilled in the art. The means and methods for measuring the refractive index are known.
[0025] The solution may be applied to the biological tissue in any manner so long as the compound surrounds the biological tissue and the biological tissue is transparent. The solution may be poured into a container to which the biological tissue is attached so that the entire tissue is immersed, or the biological tissue may be suspended in the solution in a suitable container. In one embodiment, the medium is removed from the biological tissue cultured in a dish, well, or on a membrane, and then the solution is added to cover the biological tissue. The mixture is left until the desired transparency is obtained, and then the solution is removed and the tissue is observed. In another embodiment, the biological tissue is isolated from the culture medium and transferred into a container containing the solution. The mixture is left until the desired transparency is obtained, and then the solution is removed and the tissue is observed. The application manner is not limited to the above embodiment.
[0026] Biological tissues include tissues derived from any living organism, including, but not limited to, tissues derived from animals, plants, fish, amphibians, reptiles, insects, microorganisms, etc. Biological tissues may be derived from mammals, such as humans, monkeys, dogs, cats, pigs, cows, rabbits, rats, mice, guinea pigs, etc., or may be derived from birds, such as chickens.
[0027] The biological tissue may be derived from any part of an organism. When the organism is an animal, the biological tissue may be derived from, for example, the heart, lungs, liver, kidneys, stomach, intestines, pancreas, gallbladder, reproductive organs, brain, skin, muscle, etc. The biological tissue may be a biopsy tissue, a tissue obtained by surgery, or a tissue obtained by dissection. The biological tissue may also be artificially produced. Examples of artificial biological tissue include, but are not limited to, tissues produced by the LbL method described in JP 2012-115254 A and the like. The biological tissue may be obtained by a known culture method. The biological tissue may be a spheroid. The biological tissue may be a graft. The biological tissue may be a normal tissue or a diseased tissue, for example, a cancer tissue. In this specification, the term biological tissue includes cells, cell masses, tissues, organs, organs, and individual organisms (excluding living human individuals). The biological tissue may also be decellularized tissue.
[0028] The term "alive state" refers to a cell viability in a living tissue that has been cleared using the compound of the present invention of about 30% or more, preferably about 40% or more, more preferably about 50% or more, even more preferably about 60% or more, and most preferably about 70% or more, for example, about 80% or more. The cell viability can be measured by a known method such as trypan blue staining.
[0029] When performing transparency, the tissue may be transparentized so that the transmittance of light at 600 nm at a desired site in the tissue is about 30% or more, preferably about 40% or more, more preferably about 50% or more, even more preferably about 60% or more, most preferably about 70% or more, for example, about 80% or more. The transmittance is expressed as the ratio of transmitted light to incident light. Methods and means for measuring transmittance are known to those skilled in the art. Those skilled in the art can select and determine conditions for achieving transparency, such as the selection of a compound, the concentration of a compound, the transparentization treatment time, temperature, pH, and the presence or absence of shaking, taking into consideration the type of biological tissue and the desired transparent depth.
[0030] In a further aspect, the present invention provides a composition for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and polymers of nucleotides.
[0031] The form of the composition of the present invention is not particularly limited, but is usually a solution containing the above-mentioned compound. The solution is preferably a solution in which the above-mentioned compound is dissolved in an aqueous medium. Examples of the aqueous medium include water and buffer solutions. The buffer solution is as described above. The concentration of the above-mentioned compound in the solution is as described above. Alternatively, the composition of the present invention may be in a solid form (e.g., powder, granules, pellets, etc.) or semi-solid form (e.g., paste, gel, etc.). The composition of the present invention may be diluted with an aqueous medium or dissolved in an aqueous medium before use. The composition of the present invention may further contain any compound, for example, an organic or inorganic component. The composition of the present invention can be applied to a living tissue to make the living tissue transparent in a living state. The application is as described above.
[0032] In a further aspect, the present invention provides a kit for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of nucleotides, nucleotide derivatives, polymers having nucleotides or nucleotide derivatives, and polymers of nucleotides.
[0033] The kit of the present invention includes the above-mentioned compound as an essential component. Specifically, the kit of the present invention may include a container containing the above-mentioned compound as a solution in an aqueous medium, or a container containing the above-mentioned compound as, for example, a powder, granules, pellets, paste, gel, etc. The form of the container is not particularly limited, and may be, for example, a bottle, a bag, a tube, etc. Usually, an instruction manual is attached to the kit of the present invention.
[0034] In another aspect, the present invention provides a method for observing biological tissue, which comprises making the biological tissue transparent in vivo using the method, composition, or kit of the present invention and observing the inside of the biological tissue.
[0035] In the observation method of the present invention, the living tissue cleared by using the method, composition, or kit of the present invention is observed with the naked eye or with an instrument such as a microscope. The observation means and methods are known to those skilled in the art and can be appropriately selected according to the type and size of the tissue. For example, a cleared sample may be immunostained with a fluorescently labeled antibody, and then a specific substance or site in the living tissue may be detected with a fluorescent microscope. According to the observation method of the present invention, the state of the deep part of the living tissue, such as the development of the vascular system, the production of substances, gene expression, and lesions, can be observed.
[0036] In yet another aspect, the present invention provides a method for producing a biological tissue that has been made transparent in a living state, which method is characterized by using the method, composition, or kit of the present invention.
[0037] As explained above, the methods, compositions and kits of the present invention are preferably applicable to living biological tissue, but it goes without saying that they can also be applied to non-living biological tissue.
[0038] Unless otherwise specified, the meanings of the terms used in this specification are interpreted as being in the same sense as commonly understood in the fields of chemistry, biology, pharmacology, medicine, and the like.
[0039] The present invention will be described in more detail and specifically below with reference to examples, but the scope of the present invention is not limited to these examples. EXAMPLES
[0040] Example 1. Clarifying ability of nucleotides and nucleotide polymers in a collagen model system Since collagen is the most abundant component in biological tissues, we used a collagen solution as a model for biological tissue to screen various compounds for their ability to make the material transparent. The outline of the screening experiment is as follows. An aqueous solution of the test compound was added to a multi-well plate containing an aqueous solution of sCMF (sonicated collagen micro fiber), and after standing at room temperature for a certain period of time, the apparent transparency and the transmittance at 600 nm were measured. As a result, several compounds with excellent clearing ability were found among the polymers of nucleotides and ribonucleotides. In particular, AMP, ADP, ATP, CMP, TMP and polyA were found to have high clearing ability. Among these compounds, ATP induced low cell viability, but it was thought that cell viability could be improved by adjusting the clearing conditions such as the time and temperature of the clearing treatment and the concentration of these compounds.
[0041] The clearing experiments using AMP, ADP, ATP, CMP, TMP and polyA are described below. 100 μL of 100 wt% AMP aqueous solution (refractive index 1.43), 100 wt% CMP aqueous solution (refractive index 1.42), 100 wt% TMP aqueous solution (refractive index 1.41), or 25 wt% polyA aqueous solution (refractive index 1.37) was added. The molecular weight of polyA was 100 to 500 kDa. Distilled water was added as a control. After leaving the plate at room temperature for 2 hours, the absorbance at 600 nm was measured using a plate reader (Synergy HTX). The obtained absorbance was substituted into the Lambert-Beer equation to calculate the transmittance.
[0042] The appearance of the plate after 2 hours of clearing treatment is shown in the upper panel of Figure 1, and the transmittance is shown in the lower panel of Figure 1. The transmittance was highest when AMP was used (75.6%), followed by the transmittance when PolyA was used (69.0%). The transmittances when CMP and TMP were used were 45.2% and 31.6%, respectively. EXAMPLES
[0043] Example 2 Effect of clearing treatment on cell viability The viability of cells was examined after clearing with AMP, ADP, ATP, CMP, TMP, fructose, glucose, trehalose, sucrose, antipyrine, Lapiclear 1.52, and polyA. Human dermal fibroblasts were cultured in a 24-well plate at 1.0x10 5 The cells were seeded and cultured in DMEM medium. The next day, after washing with PBS, 100% AMP aqueous solution, 100% ADP aqueous solution, 100% ATP aqueous solution, 100% CMP aqueous solution, 100% TMP aqueous solution, 100% fructose aqueous solution, 100% glucose aqueous solution, 100% trehalose aqueous solution, 100% sucrose aqueous solution, 100% antipyrine aqueous solution, Lapiclear 1.52 aqueous solution, or 25% poly A aqueous solution was added in an amount of 100 μL and incubated at 37 ° C for 30 minutes. Distilled water was added to the control. After incubation, 0.1% trypsin was added directly and incubated for 5 minutes. Cell detachment was confirmed, 3 mL of DMEM medium was added, and the cells were collected in a 15 mL centrifuge tube and centrifuged (1000 rpm, 5 minutes, 20 ° C). The supernatant was aspirated and 100 μL of DMEM medium was added. 10 μL of the solution was taken and placed in an Eppendorf tube, and 10 μL of trypan blue solution was added. 10 μL of the solution was taken and the number of cells was counted using an automatic cell counter. The results are shown in Table 1. [Table 1]
[0044] It was confirmed that a considerable number of cells survived after the clearing treatment. The survival rate was highest in the clearing treatment with AMP, followed by the survival rate with ADP. The cell survival rate was also higher when treated with CMP and TMP than when treated with Lapiclear 1.52 and antipyrine, which are known clearing agents. When polyA was used, trypan blue staining was not possible due to the high viscosity of polyA, but the clearing treatment with polyA seemed to have little effect on the survival rate (data not shown). EXAMPLES
[0045] Example 3 Effect of AMP concentration and collagen concentration on clearing Using collagen solution as a model of biological tissue, we investigated the effects of AMP and collagen concentrations on the clearing of collagen. 100μL of 0.1wt%, 0.5wt%, 1wt% and 5wt% sCMF aqueous solutions were placed in a 96-well plate, and 100μL of 10wt% (refractive index 1.35), 25wt% (refractive index 1.38), 50wt% (refractive index 1.39) and 100wt% (refractive index 1.43) AMP aqueous solutions were added. After standing at room temperature for 2 hours, the absorbance at 600nm was measured using a plate reader (Synergy HTX). The obtained absorbance was substituted into the Lambert-Beer equation to calculate the transmittance.
[0046] The appearance of the plate after 2 hours of clearing treatment is shown in the left panel of Figure 1. The relationship between sCMF concentration and transmittance when 50 wt% AMP was used is shown in the upper right panel of Figure 1. The effect of AMP concentration and sCMF concentration on transmittance is shown in Figure 2. It was found that the lower the collagen concentration, the higher the transmittance, and the higher the AMP concentration, the higher the transmittance. These results suggest that the concentration of the compound used for clearing can be adjusted depending on the thickness of the biological tissue (desired clearing depth) and the cell density of the biological tissue. EXAMPLES
[0047] Example 4: Three-dimensional tissue model transparency test (1) The experimental procedure is as follows. (1) A solution containing fibrinogen at a concentration of 2 mg / 100 μL, CMF at a concentration of 6 mg / 100 μL, and thrombin at a concentration of 1 unit / 100 μL was prepared using DMEM. (2) Place 1.0x10 human dermal fibroblast cells in an Eppendorf tube. 5 5.0x10 human umbilical vein endothelial cells 4 A cell suspension was prepared by adding 18 μL of a mixed medium of DMEM and EGM-2 and 2 μL of thrombin solution. (3) The fibrinogen solution prepared in (1) was combined with the CMF solution to make a total of 200 μL of the solution, from which 40 μL was removed and added to the cell suspension prepared in (2). (4) The cell suspension prepared in (3) was placed on a glass-bottom dish to create a 30 μL drop. (5) The drops were incubated for 2 hours, and then 2 mL of a mixed medium of DMEM and EGM-2 was added. (6) The drops were cultured at 37°C for 1 week, washed with PBS, and then fixed with paraformaldehyde for 15 minutes. (7) Fixed tissues were subjected to CD31 immunostaining and DAPI staining. (8) The specimen was subjected to a clarification treatment using 100% by weight AMP at 37°C for 30 minutes. (9) The tissues were observed using a confocal laser microscope (Olympus FV3000).
[0048] The top row of Figure 3 shows photographs of the tissue (directed perpendicular to the dish) before and after clearing. It was confirmed with the naked eye that the tissue had been completely cleared. The bottom row of Figure 3 shows immunostained images of blood vessels in the tissue (directed perpendicular to the dish) before and after clearing treatment. Before clearing treatment, the blood vessels deep in the tissue were unclear (left), but after clearing treatment, the blood vessels deep in the tissue could be clearly observed (right).
[0049] The upper panel of Figure 4 shows immunostained images (horizontal to the dish) of blood vessels in the tissue before and after clearing treatment. Almost no blood vessels were observed before clearing treatment, but after clearing treatment, blood vessels deep inside could be clearly observed. The lower right panel of Figure 4 is a confocal laser microscope photograph of the entire vascular network after clearing treatment. From this photograph, it can be confirmed that a vascular network has been formed throughout a large space of several millimeters. EXAMPLES
[0050] Example 5: Three-dimensional tissue model transparency test (2) A clearing test was carried out on a living three-dimensional tissue model. 60% by weight of AMP was used as a clearing agent, and for comparison, Lapiclear 1.52 and 61% by weight of fructose were used. The experimental procedure was the same as that of Example 4, except that the fixation with paraformaldehyde described in step (6) was not carried out.
[0051] Figure 5 shows immunostained images of blood vessels in tissue before and after clearing treatment using AMP. The top of Figure 5 shows images immediately before treatment (0 min), the left panel shows images observed vertically to the dish, and the right panel shows images observed horizontally to the dish. The bottom of Figure 5 shows images immediately after treatment (30 min), the left panel shows images observed vertically to the dish, and the right panel shows images observed horizontally to the dish. Clearing treatment with AMP made it possible to see the center of the tissue, and to observe tissues up to 200 μm deep.
[0052] Furthermore, in the same experimental system as above, after 30, 60, and 90 minutes of clearing treatment, the tissue was disintegrated with proteinase K and collagenase (1:1), and the number of viable cells was counted by trypan blue staining. The results are shown in Figure 6. The left panel of Figure 6 shows the cell viability after 30 minutes of clearing treatment with AMP, Lapiclear 1.52, and fructose. Clearing treatment with AMP did not significantly affect cell viability (cell viability 92%). On the other hand, clearing treatment with Lapiclear 1.52 and fructose clearly reduced cell viability (65% and 22%, respectively). The right panel of Figure 6 shows the relationship between the time of clearing treatment with AMP and cell viability. After 30 and 60 minutes of clearing treatment, the cell viability was very high at 92% and 90%, respectively. It was confirmed that a considerable number of cells were still alive even after 90 minutes of clearing treatment (cell viability 45%). [Industrial Applicability]
[0053] The present invention can be used in the development of pharmaceuticals, medical and biological research, and the like.
Claims
1. A method for making biological tissue transparent in a living state, comprising applying a solution containing one or more compounds selected from the group consisting of AMP, ADP and polyA to the biological tissue.
2. A composition for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of AMP, ADP and polyA.
3. A kit for making biological tissue transparent in a living state, comprising one or more compounds selected from the group consisting of AMP, ADP and polyA.
4. A method for observing a living tissue, comprising: making the living tissue transparent in a living state using the method according to claim 1, the composition according to claim 2, or the kit according to claim 3, and observing the inside of the living tissue.
5. A method for producing a biological tissue that has been made transparent in a living state, comprising using the method according to claim 1, the composition according to claim 2, or the kit according to claim 3.
Citation Information
Patent Citations
Water-soluble tissue clear solution
JP2003066035A
Methods for Phenotyping of Intact Whole Tissues
JP2016538569A
Compositions and methods for tissue clearing
US20190128785A1
Method for rendering tissue transparent, reagent for rendering tissue transparent, and tissue observation method
WO2014115206A1
Composition for preparing biomaterial with excellent light-transmitting property, and use thereof
WO2015022883A1
